Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has announced significant advancements in its circVec-AAV expression platform, showcasing a 50% boost in gene expression with its new circVec 4.0 construct. This development enhances the platform’s potential in heart and CNS disease treatments, offering improved tissue selectivity and reduced toxicity. The company’s recent R&D agreement with a major pharmaceutical company underscores its leadership in circular RNA gene expression technology, and Circio is exploring further financing options to expand its R&D operations.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapy. The company has established a unique circular RNA (circRNA) vector expression technology, known as the circVec platform, which is designed for efficient biogenesis of multifunctional circRNA inside target cells. This platform has applications in genetic medicine, cell therapy, and chronic disease, demonstrating significant improvements over conventional mRNA-based systems.
YTD Price Performance: 90.14%
Average Trading Volume: 3,650,150
Current Market Cap: NOK193.9M
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.